Skip to main content

Pharmacists’ Monitoring of ESAs Leads to Cost¬Savings

November/December 2010, Vol 3, No 6 - Conference Highlights AMCP

A pilot program in which specialty pharmacists monitored hemoglobin levels in patients whose physi­cians had requested refills of erythropoiesis­stimulating agents (ESAs) resulted in some dosing changes and sig­nificant drug cost­savings for payers.

The program was run by the Accredo Health Group in Memphis, TN, and took place for 4.5 months between June 2009 and October 2009. When an ESA refill was requested, specialty pharmacists requested hemoglobin levels from prescribers. If data were more than 8 weeks old, or if the hemoglobin level was ≥12 g/dL, the phar­macists called prescribers to discuss US Food and Drug

Administration warnings, recommend therapy changes, and document prescribing decisions.

Requests for hemoglobin measures were made for 6572 ESA refills, and 713 hemoglobin levels were not obtained. Of the total 6572 refills, 1447 (22%) required specialty pharmacist intervention (746 for elevated laboratories, 421 for outdated laboratories, and 280 others). Of the 1447 refills, 610 (42.2%) were not dispensed because of therapy holds (416), dose changes (107), cancellations (85), or other (2) rea­sons. Therapy was continued in 337 patients, despite elevated/outdated hemoglobin levels. The authors estimate that $3761 was saved per therapy hold, and $2498 per dose change; $555 was saved per member per month for therapy dose changes.

For each program month, the total drug cost­savings was estimated at $398,796; total savings during the course of the program was estimated at $1,794,529.

Although the pilot program has officially ended, ESA monitoring continues, and the authors report continued favorable acceptance by providers to supply­ing laboratory values and to the entire intervention.

Related Items
Can Technologic Innovations and Formulary Considerations Improve Healthcare Outcomes?
Charles Bankhead
June 2018 Vol 11, No 4 published on June 25, 2018 in Conference Highlights AMCP
AMCP Nexus 2017 Highlights
December 2017 Vol 10, No 9 published on January 3, 2018 in Conference Highlights AMCP
Challenges and Opportunities in Managing Type 2 Diabetes
Laura Morgan
June 2017 Vol 10, No 4 published on June 22, 2017 in Conference Highlights AMCP
Payers’ Perspective: Incorporating Real-World Evidence in Patient Care
Lilly Ostrovsky
April 2017 Vol 10, No 2 published on April 18, 2017 in Conference Correspondent, Conference Highlights AMCP
Implications of Real-World Data and Pharmacoeconomics for Managed Care
Lilly Ostrovsky
May 2016 Vol 9, No 3 published on May 25, 2016 in Conference Highlights AMCP
Last modified: August 30, 2021